Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Patients With X-linked Retinoschisis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02331173
Recruitment Status : Completed
First Posted : January 6, 2015
Last Update Posted : November 17, 2017
Sponsor:
Collaborator:
Foundation Fighting Blindness
Information provided by (Responsible Party):
Applied Genetic Technologies Corp

Brief Summary:
The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

Condition or disease Intervention/treatment
X-linked Retinoschisis XLRS Drug: Dorzolamide 2% TID or brinzolamide 1% TID

Detailed Description:
The objective of the study is to evaluate subjects with XLRS in a clinical setting and gather data on disease progression. The data from this study will enhance the understanding of the natural history of this rare disease and will facilitate appropriately powered safety studies in a future gene therapy trial in humans.

Layout table for study information
Study Type : Observational
Actual Enrollment : 66 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS)
Study Start Date : November 2012
Actual Primary Completion Date : October 2016
Actual Study Completion Date : October 2016


Group/Cohort Intervention/treatment
Main Study Group
All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
Carbonic anhydrase inhibitor sub-study
Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
Drug: Dorzolamide 2% TID or brinzolamide 1% TID

Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:

  • Topical dorzolamide 2% three times per day
  • Topical brinzolamide 1% three times per day




Primary Outcome Measures :
  1. Disease progression in subjects with XLRS [ Time Frame: Every 6 months for 18 months ]

Secondary Outcome Measures :
  1. Disease progression using microperimetry, a non-standard of care visual function test [ Time Frame: Every 6 months for 18 months ]
  2. Disease progression using electroretinograms (ERGs), a non-standard of care visual function test [ Time Frame: Every 6 months for 18 months ]
  3. Disease progression using the reading speed test, a non-standard of care visual function test [ Time Frame: Every 6 months for 18 months ]
  4. Disease progression using the contrast sensitivity test, a non-standard of care visual function test [ Time Frame: Every 6 months for 18 months ]
  5. Disease progression using a quality of life questionnaire [ Time Frame: Every 6 months for 18 months ]
  6. Change in maculoschisis while receiving carbonic anhydrase inhibitors [ Time Frame: All study visits, Months 1, 3, 6, 12, and 18 ]
  7. Change in visual function while receiving carbonic anhydrase inhibitors [ Time Frame: All study visits, Months 1, 3, 6, 12, and 18 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Potential subjects will be identified from the Oregon Retinal Degeneration Center (ORDC) database and the Retina and Ophthalmic practices at Oregon Health and Science University Casey Eye Institute, Retina Foundation of the Southwest and Kellogg Eye Center.
Criteria

Inclusion Criteria:

Main Study:

  • Clinical diagnosis consistent with XLRS
  • Documented disease causing RS1 mutation
  • 7 years of age or older
  • Able to provide informed consent/assent
  • Male

CAI sub-study:

• Presence of maculoschisis

Exclusion Criteria:

Main Study:

• Other eye diseases that might affect the results (e.g. history of retinal detachment, glaucoma, cataracts that prohibit imaging, or any other eye pathology that in the opinion of the investigator would preclude enrollment)

CAI Sub-study:

Exclusion Criteria

  • Already being treated with CAIs
  • Previous documented failure to respond to CAI treatment

Any drug-specific contraindication/precaution listed below (from www.micromedex.com):

Topical Eye Drop Dorzolamide Hydrochloride

Contraindications:

• hypersensitivity to dorzolamide products, including sulfa allergies

Precautions:

  • dorzolamide is a sulfonamide that is absorbed systemically, sulfonamide hypersensitivity reactions may occur
  • angle-closure glaucoma
  • concomitant use of oral carbonic-anhydrase inhibitors
  • conjunctivitis and lid reactions reported with chronic administration
  • moderate to severe renal (CrCl less than 30 mL/min) or hepatic insufficiency
  • ocular infection or inflammation
  • recent ocular surgery

Topical Eye Drop Brinzolamide

Contraindications:

• hypersensitivity to any component of the product, including sulfa allergies

Precautions:

  • concomitant use of oral carbonic anhydrase inhibitors is not recommended
  • contact lens use; remove contact lenses prior to administration, allow 15 minutes before reinsertion
  • hypersensitivity to sulfonamides; severe reaction may occur; discontinue if signs or symptoms appear
  • low corneal endothelial cell counts; increased risk of corneal edema
  • renal impairment, severe (CrCl less than 30 mL/min); use not recommended

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02331173


Locations
Layout table for location information
United States, Michigan
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, United States, 48105
United States, Oregon
Casey Eye Institute, Oregon Health and Sciences University
Portland, Oregon, United States, 97239
United States, Texas
Retina Foundation of the Southwest
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Applied Genetic Technologies Corp
Foundation Fighting Blindness
Investigators
Layout table for investigator information
Study Director: Matt Feinsod, MD Applied Genetics Technologies Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier: NCT02331173     History of Changes
Other Study ID Numbers: XLRS-001
First Posted: January 6, 2015    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: October 2017
Keywords provided by Applied Genetic Technologies Corp:
XLRS
RS1
maculoschisis
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinoschisis
Retinal Degeneration
Retinal Diseases
Eye Diseases
Dorzolamide
Brinzolamide
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents